

Subject Index

A

- Acarbose, insulin secretion and, 830
- Adenosine triphosphate-sensitive chloride channel, activation of, by cell swelling, cAMP, and glyburide, in insulin-secreting cells, 1461
- Adenylyl cyclase, galanin inhibition of, G_i-protein and, 453
- Adipocyte, insulin action in, BRL 49653 and, 1087
- Adipose tissue
 - abdominal, in NIDDM, 141
 - human *obese* gene expression in, 855
- Adrenergic cardiac innervation, in IDDM, myocardial iodobenzylguanidine scintigraphy of, 543
- Advanced glycosylation end products, renal and retinal microangiopathy and, 824
- Aging
 - insulin receptor mRNA splicing and, 1196
 - skeletal muscle GLUT4 and, 555
- Albuminuria, as predictor of mortality, in NIDDM, 1303
- Aldose reductase gene, retinopathy and, 727
- Aminoguanidine, diabetes onset and, in BB rat, 360
- Angiotensin I-converting enzyme gene, retinopathy and nephropathy and, in IDDM, 489
- Anticoagulant response, to activated protein C, in IDDM, 1033
- Antigen 512, pancreatic β -cell antibodies to, 1290
- Aorta, vascular endothelial growth factor receptors on, 98
- Apolipoprotein A-I, interstitial, diabetic nephropathy and, 501
- Apolipoprotein B, in IDDM, 1218
- Apolipoprotein E, overexpression of, diabetic hyperlipidemia and, 580
- Apoptosis
 - in endothelial cell, glucose-triggered, 1323
 - of pancreatic β -cell, nitric oxide and, 733
- Athlete, with IDDM, metabolism in, 471
- Autoimmune diabetes
 - adoptive transfer of, *Emv30^{null}* NOD-*scid* mouse as host for, 1392
 - cytotoxic T-cell destruction of β -cells in, intercellular adhesion molecule 1 and, 744
 - intrathymic antigen effects on CD8⁺ T-cell in, 871
 - in NOD mouse, heat shock protein 60 peptide p277 for, 1132
 - T-cell repertoire in, 354
- Autoimmunity
 - in identical twins with IDDM, 1176
 - thymus and, in BB rat, 963
- Autoregulation, in retinopathy, 603

B

- BB rat
 - diabetes onset in, nitric oxide and, 360
 - hypoglycemia in, brainstem dysfunction in, 900
 - peroxovanadium compounds in, hypoglycemic effects of, 1274

- thymus and autoimmunity in, 963
- BB/E rat, diabetes onset in, nitric oxide and, 365
- Birth weight, nephropathy and, 1405
- Blood flow
 - in leg
 - glucose uptake and, 1165
 - in NIDDM, 221
 - in retinopathy, 603
- Blood pressure, ambulatory, in nephropathy, 783. *See also* Hypertension
- Blood-brain barrier, GLUT1 in, in chronic hypoglycemia, 1399
- Body weight
 - changes in, NIDDM and, 261
 - insulin resistance and, 641
- Bone, loss and turnover of, 775
- Brainstem dysfunction, in hypoglycemia, in BB rat, 900

C

- Calcium
 - in β -cell
 - fetal, insulin secretagogue stimulation of, 118
 - ketoisocaproate-induced oscillations in, 300
 - in β TC3-cell, glucagon-like peptide I and, 767
 - glucose transport dependent on, in skeletal muscle, in hyperglycemia, 1345
- Capillary permeability, in skin and retina, IGF-I and, 1209
- Captopril, glucose and lipid metabolism and, in NIDDM patient with hypertension, 665
- Carbohydrate metabolism
 - exercise and, 1066
 - during insulin deficiency, effects of epinephrine and cortisol on, 672
 - in sciatic nerve, peripheral neuropathy and, 190
- Cardiac innervation, adrenergic, in IDDM, myocardial iodobenzylguanidine scintigraphy of, 543
- Cardiovascular disease, common soil hypothesis of, 369
- CCAAT/enhancer-binding protein β , hepatic expression of, insulin inhibition of, 267
- CD8⁺ T-cell
 - aberrant activation of, in newly diagnosed IDDM, 1414
 - intrathymic antigen effects on, 871
- Chemokine genes, and T-cell unresponsiveness to chromosome 11, 614
- Child
 - IDDM in
 - IgG antibodies to bovine serum albumin in, 1349
 - and maternal enteroviral infection during pregnancy, 408
 - of IDDM parent, IDDM risk in, 295
 - Chloride channel, ATP-sensitive, activation of, by cell swelling, cAMP, and glyburide, in insulin-secreting cells, 1461
 - Cholesterol, in IDDM, 1218

- Cholesteryl ester transfer, effect of hydroxymethylglutaryl coenzyme A reductase inhibitor on, in NIDDM, 460
- Cobalt(III)-insulin, action profile of, 1381
- Collagenase, classes I and II, islet isolation with, 227
- Corticosterone, regulation of IGF-I, IGFBPs, and growth by, in streptozotocin-induced diabetes, 1420
- Cortisol, carbohydrate metabolism and, during insulin deficiency, 672
- Coxsackie B viral infection IDDM pathogenesis and, 652
- C-peptide
 - β -cell sensitivity and, 845
 - retinopathy and, 796
- Cyclic adenosine monophosphate, activation of ATP-sensitive Cl⁻ channel by, in insulin-secreting cells, 1461
- Cytokine, nitric oxide synthase inducible by, cloning of, from islets of Langerhans, 753
- Cytokine network, insulin injection in, 859
- Cytotoxic T-cell, destruction of β -cells by, intercellular adhesion molecule 1 and, 744

D

- Dexamethasone, glucose transport and, 441
- Diabetes* journal (editorial), 1351
- Diabetic complications. *See specific disorder*
- DNA, mutations in, in diabetes-associated teratogenesis, 20
- Doxazocin, glucose and lipid metabolism and, in NIDDM patient with hypertension, 665
- DQB1*0602, protection against IDDM by, 608
- DRB1*0403, protection against IDDM by, 527

E

- Elderly
 - insulin and hypoglycemia in, 272
 - retinopathy, glucose and insulin in, 11
- Embryogenesis, glutathione depletion and oxidative stress and, 992
- Embryopathy, maternal diabetes-associated, TNF- α in, 531
- Emv30^{null}* NOD-*scid* mouse, as host for adoptive transfer of autoimmune diabetes, 1392
- Endoskeletal protein, mRNA encoding, in experimental diabetes, 25
- Endothelial cell
 - glucose-triggered apoptosis in, 1323
 - oxidative stress to, 520
- Endothelial dysfunction
 - microalbuminuria after, 561
 - pancreatic islet transplantation for, 1106
- Endothelin-1, obesity and, 431
- Energy metabolism, in sciatic nerve, peripheral neuropathy and, 190
- Enteroviral infection
 - IDDM pathogenesis and, 408, 652
 - maternal, in pregnancy, offspring IDDM and, 408
- Epinephrine, and carbohydrate metabolism during insulin deficiency, 672

- Exercise**
 insulin secretion induced by, islet transplantation and, 565
 lipid and carbohydrate metabolism and, 1066
- Experimental diabetes**
 endothelial dysfunction in, pancreatic islet transplantation for, 1106
 neuronal gene expression in, 25
- Extracellular matrix components**, glomerular, FR139317 effect on, 895
- F**
- Familial NIDDM**
 insulin resistance in, 1259
 obesity in, 418
- Fasting**, insulin receptor mRNA splicing and, 1196
- Fat**
 brown, reduced, in transgenic mice with NIDDM, insulin resistance in, 1266
 infusion of, insulin secretion and glucose utilization and, 1239
- Fatty acid(s)**
 hepatic glucose output and, 1038
 myocardial glucose uptake and, in IDDM, 537
- Fatty acid-binding protein**, intestinal, linkage of, with 2-h insulin, 1046
- Fetus**, β -cell of, calcium in, insulin secretagogue stimulation of, 118
- Fibronectin**, mesangial cell synthesis of, thromboxane and, TGF- β and, 335
- FR139317**, effect of, on glomerular extracellular matrix components and growth factors, 895
- G**
- Galanin**, adenylyl cyclase inhibition by, G-protein and, 453
- Gender**, insulin sensitivity and, 31
- Gestational diabetes**
 insulin secretion and action after, 506
 K^{ATP} channel-like protein in, insulin secretion and, 597
 prediction of NIDDM after, 586
 proinsulin in, 911
- GK-Wistar hybrid rat**, hyperglycemia in, 1280
- Glipizide/insulin**, for sulfonylurea failure, 165
- Glomerular mesangial cell**, contractility of, 759
- Glomerulopathy**, extracellular matrix and growth factors in, FR139317 effect on, 895
- Glucagon**, hepatic glycogenolysis in response to, 185
- Glucagon-like peptide I**
 degradation of, 1126
 glucose disposition and, 1433
 reduction of postprandial glycemic excursions by, 626
 β TC3-cell calcium and, 767
- Glucagon-like peptide I(7-36)**, in Zucker rat, insulin secretion and, 495
- Glucagon-like peptide I receptor antagonist**, incretin effect and, 16
- Glucan-1,4- α -glucosidase activity**, acarbose and, 830
- Glucocorticoids**, insulin resistance induced by, 441
- Glucosamine**, glycogen synthase regulation by, 314
- Glucose**
 apoptosis triggered by, in endothelial cell, 1323
 disposition of, glucagon-like peptide I and, 1433
 in elderly, 11
 glycogen synthase regulation by, 314
 hepatic output of, free fatty acid and, 1038
 impaired oxidation of, after oxidative stress to endothelial cell, 520
 implantable sensor for, 1005
 insensitivity to, palmitate-induced, in pancreatic β -cell, pyruvate dehydrogenase kinase and, 394
 kinetics of, insulin sensitivity and, 954
 metabolism of
 effects of captopril, nifedipine, and doxazocin on, in NIDDM patient with hypertension, 665
 fat infusion and, 1239
 in insulinoma patient, 837
 in skeletal muscle, 936
 phosphorylation of, hexokinase II gene regulation and, 1426
 reduction of degradative enzymes by, in mesangial cell, 929
 tyrosine phosphorylation induced by, in β TC3-cell, 802
- Glucose tolerance test**
 C-peptide data from, β -cell sensitivity and, 845
 early postpartum, 586
 intravenous, HLA and, in islet cell antibody-positive siblings, 1021
- Glucose transport**
 Ca²⁺-dependent, in skeletal muscle, in hyperglycemia, 1345
 dexamethasone and, 441
 in insulin-resistant skeletal muscle
 effects of okadaic acid, vanadate, and phenylarsine oxide on, 682
 hypoxia and, 695
 in skeletal muscle, after oral glucose load, 1362
- Glucose uptake**
 blood flow in leg and, 1165
 in contracting skeletal muscle, 210
 myocardial, hyperglycemia and, 537
- Glucose-dependent insulinotropic polypeptide receptor**, in human pancreatic islet, chromosomal localization of, 1202
- GLUT1**, in blood-brain barrier, in chronic hypoglycemia, 1399
- GLUT2**
 in β -cell, with and without NIDDM, 1369
 loss of, in transplanted islets, 75
- GLUT4**
 hyperglycemia-induced translocation of, in skeletal muscle, 646
 in skeletal muscle, aging and, 555
- Glutamic acid decarboxylase antibodies**, 1290
 disease sensitivity and specificity of, 52
 assays for, 636
 identification of, 216
- Glutamine:fructose-6-amidotransferase**, glycogen synthase regulation by, 314
- Glutathione**, depletion of, embryogenesis and, 992
- Glyburide**, activation of ATP-sensitive Cl⁻ channel by, in insulin-secreting cells, 1461
- Glycemic control**, poor, as predictor of mortality, in NIDDM, 1303
- Glycemic excursion**, postprandial, glucagon-like peptide I and, 626
- Glycemic exposure**, retinopathy and, 968
- Glycogen synthase**
 hexosamine regulation of, 314
 in skeletal muscle, 1099
- Glycogenolysis**, hepatic, in response to glucagon, 185
- G-protein**. *See* Protein(s)
- Granzyme A**, after T-cell transfer, 112
- Growth**, corticosterone regulation of, in streptozotocin-induced diabetes, 1420
- Growth factor(s)**
 β -cell proliferation and, 1458
 glomerular, FR139317 effect on, 895
- Growth-associated protein**, mRNA encoding, in experimental diabetes, 25
- H**
- HbA_{1c}**, retinopathy and, 968
- Heart**
 diabetic, intracellular pH and, 196
 insulin sensitivity in, gender and, 31
- Heat shock protein 60 peptide p277**, for autoimmune diabetes, in NOD mouse, 1132
- Hexokinase**
 amino acid substitutions in, in NIDDM, 330, 340, 347
 genetic structure of, 290
 glucose phosphorylation and, 1426
 in isolated pancreatic β -cell, 1328
- Hexosamine**
 regulation of glycogen synthase by, 314
 synthesis pathway for, in muscle and liver, effects of diabetes and hyperglycemia on, 1438
- Hexose monophosphate shunt**, in hyperglycemic lens, 810
- Hirata's disease**, immunogenetic determinants of, 1227
- HLA-DQB1*0602**, protection against IDDM by, 608
- HLA-DRB1*0403**, protection against IDDM by, 527
- HOXD8 locus**, linkage of, to IDDM, 132
- Human leukocyte antigen**
 intravenous glucose tolerance tests and, in islet cell antibody-positive siblings, 1021
 physical property changes and, 125
 retinopathy and, 1334
- Hydroperoxide**, plasma levels of, in NIDDM, 1054
- 12-Hydroxyeicosatetraenoic acid**, renin response to, 321
- Hyperglycemia**
 acute, GLUT4 translocation induced by, in skeletal muscle, 646
 in GK-Wistar hybrid rat, 1280
 lens in, hexose monophosphate shunt in, 810
 and muscle and liver hexosamine synthesis pathway, 1438
 renal transport and, 446
 short-term, hypoglycemia after, 513
 skeletal muscle Ca²⁺-dependent glucose transport in, 1345
 thrombin formation induced by, oxidative stress and, 924
- Hyperinsulinemia**
 hepatic apolipoprotein B-100 secretion and, in NIDDM, 1059
 protein and glucose metabolism in, in insulinoma patient, 837
- Hyperlipidemia**, apolipoprotein E overexpression and, 580
- Hyperphagia**, CNS insulin infusion and, 147
- Hypertension**. *See also* Blood pressure

- with NIDDM, glucose and lipid metabolism in, effects of captopril, nifedipine, and doxazosin on, 665
- Hypertriglyceridemia, N0-1886 for, in streptozotocin-induced diabetes, 414
- Hypoglycemia
- brainstem dysfunction in, in BB rat, 900
 - chronic, blood-brain barrier GLUT1 in, 1399
 - counterregulation of, in skeletal muscle, 423
 - in elderly, 272
 - human insulin in, 257
 - peroxovanadium compounds and, in BB rat, 1274
 - after short-term hyperglycemia, 513
- Hypothalamus, ventromedial, in counterregulation, 180
- I**
- IDDM**
- activated protein C response in, 1033
 - adrenergic cardiac innervation in, myocardial iodobenzylguanidine scintigraphy of, 543
 - angiotensin I-converting enzyme gene in, retinopathy and nephropathy and, 489
 - in athletes, metabolism in, 471
 - β -cell granule antigens in, T-cell responses to, 278
 - in child
 - effect of maternal enteroviral infection during pregnancy on, 408
 - IgG antibodies to bovine serum albumin in, 1349
 - parental IDDM and, 295
 - DQB1*0602 protection against, 608
 - DRB1*0403 protection against, 527
 - HLA-DQ variations in, physical property changes and, 125
 - HOXD8 locus and, 132
 - identical twins with, autoimmunity in, 1176
 - immunogenetic determinants of, 1029
 - insulin gene mapping in, 620
 - intravenous insulin as protection against, in NOD mouse, 906
 - levels of lipoprotein(a), apolipoprotein B, and cholesterol in, 1218
 - lipid and carbohydrate metabolism in, exercise and, 1066
 - microalbuminuria in, after endothelial dysfunction, 561
 - myocardial glucose uptake and, 537
 - nephropathy in
 - incidence of, 739
 - interstitial apolipoprotein A-I and, 501
 - newly diagnosed, aberrant activation of CD8⁺ T-cell in, 1414
 - in NOD mouse, genetic heterogeneity of, 1186
 - pancreatic interferon in, 658
 - pathogenesis of, enteroviral infection and, 408, 652
 - positional cloning in, 139
 - postprandial glycemic excursions in, glucagon-like peptide I and, 626
 - postprandial proteolysis in, 203
 - prevention of, 859
 - recent-onset, platelet activation in, 890
 - transfer of, to NOD mouse, by islet-infiltrating lymphocyte, 550
- Identical twins, with IDDM, autoimmunity in, 1176
- IFN. *See* Interferon
- IGF-I. *See* Insulin-like growth factor I
- IGFBPs. *See* Insulin-like growth factor-binding proteins
- IL. *See* Interleukin
- Immunogenetic determinants, IDDM predictability and, 1029
- Immunoglobulin G antibodies, to bovine serum albumin, in child with IDDM, 1349
- Implantable glucose sensor, 1005
- Incretin, glucagon-like peptide 1 receptor antagonist and, 16
- Inositol transport, hyperglycemia and, in renal tubule cells, 446
- Insulin**
- antilipolytic effect of, phosphodiesterase III and, 1170
 - in elderly, 11, 272
 - human, in hypoglycemia, 257
 - injection of, into cytokine network, 859
 - intracerebroventricular infusion of, diabetic hyperphagia and, 147
 - intravenous, as protection against IDDM, in NOD mouse, 906
 - myocardial glucose uptake and, in IDDM, 537
 - in nondiabetic offspring of diabetic parent, 1156
 - ob gene and, 1467
 - platelet antiaggregating effect induced by, in obesity and NIDDM, 1318
 - two-hour
 - linkage of intestinal fatty acid-binding protein with, 1046
 - segregation analysis of, 284
 - vasodilation and sympathoexcitation induced by, in skeletal muscle, 641
- Insulin action**
- BRL 49653 and, 1087
 - in contracting skeletal muscle, 210
 - after gestational diabetes, 506
 - physical training and, 1010
 - on protein and glucose metabolism, in insulinoma patient, 837
 - rate-limiting steps of, 947
 - in skeletal muscle, 936
- Insulin autoimmune syndrome, monoclonal and polyclonal, immunogenetic determinants of, 1227**
- Insulin deficiency, carbohydrate metabolism in, effects of epinephrine and cortisol on, 672**
- Insulin gene**
- exact length of 5'-flanking polymorphism class 1 alleles in, 1296
 - mapping of, 620
- Insulin gene promoter, nomenclature in, 1002**
- Insulin receptor**
- genetic regulation of, effects of fasting, aging, and diabetes on, 1196
 - mutations in, in NIDDM, 1081
- Insulin receptor kinase, in skeletal muscle, in NIDDM, 1310**
- Insulin resistance**
- in familial NIDDM, 1259
 - glucocorticoid-induced, 441
 - hexokinase II in, 43, 340, 347
 - hyperglycemia-induced, hypoglycemia pathogenesis and, 513
 - increased, as NIDDM risk factor, 1386
 - in lean patient, 641
 - obesity and, 1121
 - in skeletal muscle
 - antiglucocorticoids and, 718
 - 2-deoxyglucose transport in, effects of okadaic acid, vanadate, and phenylarsine oxide on, 682
 - glucose transport in, hypoxia and, 695
 - in transgenic mice with reduced brown fat, 1266
- Insulin response, acute**
- chromosome 1p and, 478
 - defect in, insulin secretion and, 984
- Insulin secretagogue, fetal β -cell calcium and, 118**
- Insulin secretion**
- acarbose and, 830
 - decreased, as NIDDM risk factor, 1386
 - defect in, insulin resistance and, 984
 - exercise-induced, islet transplantation and, 565
 - fat infusion and, 1239
 - after gestational diabetes, 506
 - glucagon-like peptide I(7-36) and, in Zucker rat, 495
 - K_{ATP} channel-like protein and, 592, 597
 - in maturity-onset diabetes of the young, genetic defect and, 699
 - in pancreatic β -cell, H₂O₂-induced activation of K⁺ channel and, 878
 - from pancreatic β -cell, monitoring of, 1213
- Insulin sensitivity**
- gender and, 31
 - glucose and lactate kinetics and, 954
 - minimal model analysis and isoglycemic clamp of, 631
- Insulinitis, induction of, in nude mouse, 49**
- Insulin-like growth factor I**
- corticosterone regulation of, in streptozotocin-induced diabetes, 1420
 - effect of, on capillary permeability in skin and retina, 1209
 - retinopathy and, 161
- Insulin-like growth factor-binding proteins, corticosterone regulation of, in streptozotocin-induced diabetes, 1420**
- Insulinoma, protein and glucose metabolism in, 837**
- Insulin-stimulated protein kinase, genetics of, in NIDDM, 90**
- Intercellular adhesion molecule 1, on pancreatic β -cell, and cytotoxic T-cell destruction of β -cells, 744**
- Interferon, pancreatic, in IDDM, 658**
- Interferon- γ , antibody to, functions of, in adult pancreas, 1161**
- Interleukin-1 β , islet protein synthesis and, 400**
- Interleukin-6, hybridization of, in nephropathy, 1233**
- Intestinal fatty acid-binding protein, linkage of, with 2-h insulin, 1046**
- Intrathymic antigen, effects of on CD8⁺ T-cell, 871**
- Islet cell. *See* Pancreatic β -cell**
- Islet cell antibody-positive siblings, HLA and intravenous glucose tolerance tests in, 1021**
- Islet cell antigen 512 autoantibody, radioassay for, 1340**
- Islet-1 screening, in NIDDM, 689**
- Islets of Langerhans, cloning of cytokine-inducible nitric oxide synthase from, 753**
- K**
- Kallikrein, renal, hyperfiltration and, 156
 - K⁺ channel, H₂O₂-induced activation of, insulin secretion and, in pancreatic β -cell, 878
 - K⁺ channel-like protein, insulin secretion and, 592, 597
 - Ketoacidosis, obesity and, 790

- Ketosisopratoate, calcium oscillations and, in pancreatic β -cell, 300
 Kidney, diabetic, TGF- β in, 1139
 Kinin, renal hyperfiltration and, 156
- L**
 L-686,398, action mechanisms of, 47
 Lactate kinetics, insulin sensitivity and, 954
 Leg, blood flow in
 glucose uptake and, 1165
 in NIDDM, 221
 Lens, hyperglycemic, hexose monophosphate shunt in, 810
 Lipid metabolism
 effects of captopril, nifedipine, and doxazocin on, in NIDDM patient with hypertension, 665
 exercise and, 1066
 Lipoprotein(s)
 effect of hydroxymethylglutaryl coenzyme A reductase inhibitor on, in NIDDM, 460
 low density
 oxidation of, in NIDDM, 60
 subfractions of, 1093
 Lipoprotein(a), in IDDM, 1218
 Lipotoxicity, in obesity-dependent NIDDM, 863
- Liver**
 apolipoprotein B-100 secretion in, hyperinsulinemia and, in NIDDM, 1059
 CCAAT/enhancer-binding protein β expression in, insulin inhibition of, 267
 glucose output of, free fatty acid and, 1038
 glycogenolysis in, in response to glucagon, 185
 hexosamine synthesis pathway in, effects of diabetes and hyperglycemia on, 1438
 Lymphocyte, islet-infiltrating, transfer of diabetes by, 550
 Lymphohematopoietic cell, growth of, in *Emv30^{null}* NOD-*scid* mouse, 1392
- M**
 Major histocompatibility complex I, class I, in NOD mouse, 572, 1114
 MAP. See Mitogen-activated protein kinase
 Maternal diabetes, embryopathy and, TNF- α in, 531
 Maturity-onset diabetes of the young
 K_{ATP} channel-like protein in, insulin secretion and, 597
 locus for, in NIDDM, 1243
 Mesangial cell
 degradative enzymes in, glucose reduction of, 929
 fibronectin synthesis in, thromboxane and, TGF- β and, 335
 glomerular, contractility of, 759
 Metabolism, in athlete with IDDM, 471
 MHC. See Major histocompatibility complex
 Microalbuminuria, after endothelial dysfunction, 561
 Microangiopathy, advanced glycosylation end products and, 824
 Microvascular function, physiology of, 721
 Mitogen-activated protein kinase, in skeletal muscle, vanadium and, 1147
 MODY gene
 insulin secretory defects in, 699
 localization of, 1408
 N^G-Monomethylarginine, diabetes onset and, in BB rat, 360
- Mortality prediction, in NIDDM, albuminuria and glycemic control in, 1303
 mRNA, encoding endoskeletal and growth-associated proteins, in experimental diabetes, 25
 Muscle, hexosamine synthesis pathway in, effects of diabetes and hyperglycemia on, 1438
- N**
 NADPH supply, after oxidative stress to endothelial cell, 520
 Na⁺/H⁺ exchanger, phosphorylation and activity of, in nephropathy, 1180
 Na⁺/K⁺ exchanger, turnover of, glucose and, 382
 Na⁺-K⁺-ATPase, hyperglycemia and, in renal tubule cells, 446
 Nephropathy
 ambulatory blood pressure in, 783
 angiotensin I-converting enzyme gene and, 489
 birth weight and, 1405
 IL-6 hybridization in, 1233
 incidence of, 739
 interstitial apolipoprotein A-I and, 501
 Na⁺/H⁺ exchanger phosphorylation and activity in, 1180
 Na⁺/K⁺ exchanger turnover in, glucose and, 382
 Neuronal gene expression, in experimental diabetes, 25
 Neuropathy
 clinical trials in, 1355
 peripheral, carbohydrate and energy metabolism in sciatic nerve and, 190
 sorbitol dehydrogenase inhibition and, 234
 Neuropeptide gene, CNS insulin infusion and, 147
 Nicotinamide, pharmacokinetics of, 152
- NIDDM**
 ambulatory blood pressure in, 783
 effect of hydroxymethylglutaryl coenzyme A reductase inhibitor on lipoproteins and cholesteryl ester transfer in, 460
 in elderly, insulin and hypoglycemia in, 272
 end-stage renal disease in, 1375
 familial, insulin resistance in, 1259
 genetics of protein phosphatase 1 and insulin-stimulated protein kinase in, 90
 after gestational diabetes, prediction of, 586
 glucose metabolism and insulin action in, in skeletal muscle culture, 936
 hepatic apolipoprotein B-100 in, hyperinsulinemia and, 1059
 hexokinase II in, amino acid substitutions in, 330, 340, 347
 hypertension with, glucose and lipid metabolism in, effects of captopril, nifedipine, and doxazocin on, 665
 insulin receptor mRNA splicing and, 1196
 insulin receptor mutations in, 1081
 insulin resistance in, in transgenic mice with reduced brown fat, 1266
 insulin secretion and resistance as risk factors for, 1386
 insulin sensitivity in, minimal model analysis and isoglycemic clamp of, 631
 insulin/sulfonylurea therapy in, 165
 islet-1 screening in, 689
 K_{ATP} channel-like protein in, insulin secretion and, 592, 597
 leg blood flow in, 221
 low-density lipoprotein oxidation in, 60
- MODY* locus in, 1243
 molecular biological studies of, 1
 mortality predictions in, albuminuria and glycemic control in, 1303
 obesity and
 familial relationships between, 418
 insulin resistance and, 1121
 insulin-induced platelet antiaggregating effect in, 1318
 lipotoxicity in, 863
 pancreatic β -cell in, GLUT2 in, 1369
 physical training in, insulin action and, 1010
 plasma hydroperoxide levels in, 1054
 plasminogen activator inhibitor 1 activity in, 37
 prevention of, 483
 prohormone convertase 2 gene in, 389
 proinsulin as marker for, 173
rad locus in, 242
 remission of, prolongation of, by sulfonylurea therapy, 466
 in siblings, human *obese* gene in, 999
 six-year therapy of, 1249
 skeletal muscle insulin receptor kinase in, 1310
 tissue factor pathway inhibition in, 80
 visceral fat and, 141
 weight changes and, 261
 Nifedipine, glucose and lipid metabolism and, in NIDDM patient with hypertension, 665
- Nitric oxide**
 diabetes onset and
 in BB rat, 360
 in BB/E rat, 365
 pancreatic β -cell apoptosis and, 733
 Nitric oxide synthase, cytokine-inducible, cloning of, from islets of Langerhans, 753
 N^ω-Nitro-L-arginine methyl ester, diabetes onset and, in BB/E rat, 365
 NO-1886, in streptozotocin-induced diabetes, 414
- NOD mouse**
 autoimmune diabetes in, heat shock protein 60 peptide p277 for, 1132
 B7-1 acceleration of diabetes in, 326
 IDDM in, genetic heterogeneity of, 1186
 intravenous insulin in, as protection against IDDM, 906
 MHC class I and *Tap* expression in, 572
 self-peptide MHC class I reactivity in, 1114
 T-cell unresponsiveness to chromosome 11 in, 614
 thymus and pancreas transplantation from, into nude mouse, 49
 transfer of diabetes to, by islet-infiltrating lymphocyte, 550
- Nude mouse**
 transplantation of NOD mouse thymus and pancreas into, 49
 transplantation of rat and porcine islets into, 104
- O**
Obese gene, human
 adipocyte-specific expression of, 855
 in NIDDM-affected siblings, 999
 Obesity
 endothelin-1 and, 431
 genetics of, insulin and, 1467
 insulin resistance and, 1121
 ketoacidosis and, 790
 NIDDM and
 familial relationships between, 418

- insulin resistance and, 1121
 insulin-induced platelet antiaggregating effect in, 1318
 lipotoxicity in, 863
 Okadaic acid, effect on glucose transport, in insulin-resistant skeletal muscle, 682
 Oxidative stress
 in diabetic vasculature, islet transplantation reversal of, 884
 embryogenesis and, 992
 hyperglycemia-induced thrombin formation and, 924
- P**
 Palmitate, glucose insensitivity induced by, in pancreatic β -cell, pyruvate dehydrogenase kinase and, 394
 Pancreas
 IFN in, in IDDM, 658
 from NOD mouse, transplantation of, into nude mouse, 49
 Pancreatic β -cell
 antibodies to antigen 512 and glutamic acid decarboxylase in, 1290
 apoptosis of, nitric oxide and, 733
 ATP-sensitive Cl^- channel in, activation of, by cell swelling, cAMP, and glyburide, 1461
 B7-1 in, acceleration of diabetes by, in NOD mouse, 326
 calcium in, ketoisocaproate-induced oscillations in, 300
 cytotoxic T-cell destruction of, intercellular adhesion molecule 1 and, 744
 dysfunctioning of, in Zucker rat, 1447
 fetal, calcium in, insulin secretagogue stimulation of, 118
 GLUT2 in, with and without NIDDM, 1369
 growth factor/matrix-induced proliferation of, 1458
 growth of, dynamics of, 249
 human, glucose-dependent insulinotropic polypeptide receptor in, chromosomal localization of, 1202
 insulin secretion in
 H_2O_2 -induced activation of K^+ ATP channel and, 878
 monitoring of, 1213
 isolated, hexokinase activity in, 1328
 isolation of, with collagenase classes I and II, 227
 molecular genetics and clinical research on, in diabetes, 705
 phosphofructokinase isozymes in, 1285
 preparation, xenotransplantation, and function of, 375
 protein synthesis in, IL-1 β and, 400
 pyruvate dehydrogenase kinase in, palmitate-induced glucose insensitivity and, 394
 transplantation of
 for endothelial dysfunction, 1106
 exercise-induced insulin secretion and, 565
 loss of GLUT2 and, 75
 into nude mouse, from rat and pig, 104
 reversal of oxidative stress in vasculature by, 884
 Pancreatic β -cell granule antigens, T-cell responses to, in IDDM, 278
 Parental diabetes, nondiabetic offspring of, proinsulin and insulin levels in, 1156
 Peroxovanadium compounds, hypoglycemic effects of, in BB rat, 1274
 pH, intracellular, in diabetic heart, 196
- Phenylarsine oxide, effect on glucose transport, in insulin-resistant skeletal muscle, 682
 Phosphodiesterase III, in antilipolytic effect of insulin, 1170
 Phosphodiesterase inhibitor, L-685,398 as, 47
 Phosphofructokinase isozymes, in pancreatic islets, 1285
 Physical training, insulin action and, 1010
 Plasminogen activator inhibitor 1, in NIDDM, 37
 Platelet, insulin-induced antiaggregating effect in, in obesity and NIDDM, 1318
 Platelet activation, in recent-onset IDDM, 890
 Positional cloning, in IDDM, 139
 Pregnancy. *See also* Gestational diabetes
 enteroviral infection during, offspring IDDM and, 408
 5'-Flanking polymorphism, in insulin gene, class 1 alleles of, exact lengths of, 1296
 Prohormone convertase 2 gene, in NIDDM, 389
 Proinsulin
 conversion of, in transfected COS cells, 1075
 in gestational diabetes, 911
 as NIDDM marker, 173
 in nondiabetic offspring of diabetic parent, 1156
 radioimmunoassay of, 437
 Protein(s)
 G_i -protein, and inhibition of adenylyl cyclase by galanin, 453
 G_o -protein, somatostatin coupling to, 85
 islet synthesis of, IL-1 β and, 400
 metabolism of, in insulinoma patient, 837
 Protein C, activated, anticoagulant response to, in IDDM, 1033
 Protein kinase, insulin-stimulated, genetics of, in NIDDM, 90
 Protein kinase C, hyperglycemia and, in renal tubule cells, 446
 Protein phosphatase 1, genetics of, in NIDDM, 90
 Proteinuria, gross, long-term incidence of, 916
 Proteolysis, postprandial, in IDDM, 203
 Pyruvate dehydrogenase kinase, in pancreatic β -cell, palmitate-induced glucose insensitivity and, 394
- R**
rad locus, in NIDDM, 242
 Renal disease, end-stage, in NIDDM, 1375
 Renal hyperfiltration, kinins and, 156
 Renal microangiopathy, advanced glycosylation end products and, 824
 Renal transport, hyperglycemia and, 446
 Renin, response of, to 12-hydroxyeicosatetraenoic acid, 321
 Retina
 capillary permeability in, IGF-I and, 1209
 microangiopathy in, advanced glycosylation end products and, 824
 vascular endothelial growth factor receptors on, 98
 Retinopathy
 aldose reductase gene and, 727
 angiotensin I-converting enzyme gene and, 489
 blood flow and autoregulation in, 603
 C-peptide and, 796
 in elderly, 11
 HbA_{1c} and, 968
 HLA-A24 and, 1334
 IGF-I and, 161
- Ribosomal S6 kinase, in skeletal muscle, vanadium and, 1147
 RU486, and insulin resistance in skeletal muscle, 718
- S**
 Sciatic nerve, carbohydrate and energy metabolism in, peripheral neuropathy and, 190
 Siblings, islet cell antibody-positive, HLA and intravenous glucose tolerance tests in, 1021
 Skeletal muscle
 Ca^{2+} -dependent glucose transport in, in hyperglycemia, 1345
 counterregulation of hypoglycemia in, 423
 glucose metabolism in, 936
 glucose transport in
 dexamethasone and, 441
 after oral glucose load, 1362
 glucose uptake in, 210
 GLUT4 in, aging and, 555
 glycogen synthase gene in, 1099
 hyperglycemia-induced translocation of GLUT4 in, 646
 insulin action in, 936
 insulin receptor kinase in, in NIDDM, 1310
 insulin sensitivity in, gender and, 31
 insulin-induced vasodilation and sympathoexcitation in, 641
 insulin-resistant
 antigluco-corticoids and, 718
 2-deoxyglucose transport in, effects of okadaic acid, vanadate, and phenylarsine oxide on, 682
 glucose transport in, hypoxia and, 695
 MAP and ribosomal S6 kinases in, vanadium and, 1147
 Skin, capillary permeability in, IGF-I and, 1209
 Somatostatin, coupling of, to G_o -protein, 85
 Sorbitol dehydrogenase, vascular and neural dysfunction and, 234
 Streptozotocin-induced diabetes
 corticosterone regulation of IGF-I, IGF-BPs, and growth in, 1420
 effect of NO-1886 in, 414
 in mB7-1 transgenic mouse, 816
 T-cell repertoire in, 354
 vascular and neural dysfunction in, sorbitol dehydrogenase inhibition and, 234
 Sulfonyleurea therapy
 failure of, insulin/glipizide for, 165
 prolonging of NIDDM remission by, 466
 Sympathoexcitation, insulin-induced, in skeletal muscle, 641
- T**
Tap, MHC class I and, in NOD mouse, 572
 βTC -6 cell, morphological and functional characterization of, 306
 βTC -3 cell, glucose-induced tyrosine phosphorylation in, 802
 T-cell. *See also* CD8⁺ T-cell; Lymphocyte cytotoxic. *See* Cytotoxic T-cell
 reactivity of, to β -cell granule antigens, in IDDM, 278
 in streptozotocin-induced diabetes, 354
 transfer of, TNF- α and granzyme A after, 112
 unresponsiveness of, to chromosome 11 in, 614
 Teratogenesis, diabetes-associated, DNA mutations in, 20
 TGF. *See* Transforming growth factor- β

Thrombin, hyperglycemia-induced formation of, oxidative stress and, 924
Thromboxane, and mesangial cell fibronectin synthesis, TGF- β and, 335

Thymus

autoimmunity and, in BB rat, 963
from NOD mouse, transplantation of, into nude mouse, 49

Tissue factor pathway, inhibition of, in NIDDM, 80

TNF- α . *See* Tumor necrosis factor- α

Transforming growth factor- β

in diabetic kidney, 1139

in thromboxane action on mesangial cell fibronectin synthesis, 335

Tumor necrosis factor- α

in embryopathy associated with maternal diabetes, 531

after T-cell transfer, 112

Twins, identical, with IDDM, autoimmunity in, 1176

Tyrosine phosphorylation, glucose-induced, in β TC3-cell, 802

U

U.K. Prospective Diabetes Study 16, 1249

V

Vanadate, effect on glucose transport, in insulin-resistant skeletal muscle, 682

Vanadium, effect on MAP and ribosomal S6 kinases, in skeletal muscle, 1147

Vascular dysfunction, sorbitol dehydrogenase inhibition and, 234

Vascular endothelial growth factor receptor, retinal and aortic, 98

Vasculature, oxidative stress in, islet transplantation reversal of, 884

Vasodilation, insulin-induced, in skeletal muscle, 641

Ventromedial hypothalamus, in counterregulation, 180

W

Weight. *See* Body weight

Wisconsin Epidemiologic Study of Diabetic Retinopathy, 796

X

Xenotransplantation, of pancreatic β -cell, 375

Z

Zucker rat

β -cell dysfunction in, 1447

glucagon-like peptide I(7-36) in, insulin secretion and, 495

insulin secretory defect in, insulin resistance and, 984

Author Index

A

Abdel-Halim, S.M., 1280
 Abe, R., 816
 Abrams, L., 936
 Abumrad, N.N., 672
 Adams, M.B., 884, 1106
 Adelman, J., 597
 Agosta, F.G., 60
 Aiello, L.P., 98
 Akazawa, S., 992
 Akelsen, H.E., 621
 Åkerblom, H.K., 652, 1021
 Alavi, N., 929
 Alper, C.A., 608
 Alshami, A., 555
 Amano, K., 744
 Amiel, S.A., 257
 Andersen, H.U., 400, 753
 Andersson, A., 1280
 Anfossi, G., 1318
 Angelico, M.C., 295
 Annibale, B., 513
 Antonipillai, I., 321
 Aoki, M., 689
 Ardehali, H., 290
 Arden, S.D., 278
 Armour, J.C., 1005
 Armstrong, M.B., 85, 306
 Arner, P., 1170
 Asahina, T., 520
 Ashcroft, F.M., 597
 Ashcroft, S., 1002
 Atwood, L.D., 284
 Auboeuf, D., 1196
 Awdeh, Z.L., 608
 Azevedo, J.L., Jr., 682, 695

B

Babu, S.R., 1340
 Baird, J.D., 365
 Baldoncini, R., 431
 Baloga, J., 1121
 Banerji, M.A., 141, 466
 Bang, L.E., 783
 Bannai, M., 1227
 Barnett, M.A., 816
 Bartoli, E., 924
 Barton, M., 1239
 Baskin, D.G., 147
 Bastyr, E.J., III, 1066
 Basu, S., 1375
 Battezzati, A., 837
 Baufays, L., 531
 Baumann, E.E., 871
 Baumgartner-Parzer, S.M., 1323
 Beattie, G.M., 1458
 Behme, M.T., 626
 Beisswenger, P.J., 824
 Belgian Diabetes Registry, 527
 Bell, G.I., 592, 597, 699, 999, 1408, 1447
 Bellini, C., 431
 Bellomo, G., 60
 Benecke, H., 1266
 Benito, C., 1369
 Bennett, P.H., 261, 418, 483
 Bennett, S.T., 621

Benson, E.A., 1227
 Berger, J., 67
 Bergman, R.N., 954, 1038
 Bergstrom, R.W., 173
 Bernard, M., 196
 Berti, L., 646
 Betteridge, D.J., 1054
 Bevan, A.P., 1274
 Beverdam, F.H., 501
 Beylot, M., 1196
 Bhatnagar, D., 460
 Bianchi, E., 837
 Biolo, G., 203
 Biswas, C., 67
 Bjørbaek, C., 90, 347
 Blangero, J., 284
 Bloch, T.N., 354
 Boado, R.J., 1399
 Boden, G., 1239
 Boel, E., 753
 Bogardus, C., 478
 Bokvist, K., 767
 Bolinder, J., 1170
 Bollati, P., 60
 Bolli, G.B., 513
 Bonifacio, E., 636
 Bonner-Weir, S., 75, 104
 Borch-Johnsen, K., 1303
 Borg, L.A.H., 830
 Borg, M.A., 180
 Borg, W.P., 180
 Bosch, F., 267
 Bossenmaier, B., 646
 Boulton, A.J.M., 460
 Bourey, R., 471
 Bowsher, R.R., 1156
 Boyko, E.J., 173
 Brady, E.J., 67
 Bragg, K.L., 1259
 Braithwaite, S.S., 43
 Brenner, B.M., 1405
 Brinck-Johnsen, T., 824
 Brown, T.R., 810
 Bruining, G.J., 278
 Brunel, P., 631
 Brunetti, P., 513
 Brunzell, J.D., 1218
 Bucala, R., 20, 824
 Buchanan, T.A., 586
 Buckingham, F., 871
 Buderer, N.F., 775
 Burzacca, S., 1318
 Buse, M.G., 1438
 Byrne, M.M., 699

C

Calderone, S., 513
 Caldwell, J.S., 243
 Cambien, F., 489
 Canessa, M.L., 665
 Carey, J.O., 682, 695
 Carnaud, C., 112
 Casals, M.M.C., 790
 Cavalot, F., 1318
 Cawthorne, M.A., 1087
 Cerami, A., 20
 Ceriello, A., 924

Chaiken, R.L., 141, 466
 Chang, K., 234
 Charlton, B., 550
 Chen, H.-M., 572
 Chen, X., 1147, 1239
 Cherif, D., 1202
 Cherrington, A.D., 672
 Childhood Diabetes in Finland (DiMe) Study Group, 652, 1021
 Chiu, K.C., 1259
 Christianson, S.W., 1392
 Chung, S.S.-M., 727
 Ciaraldi, T.P., 936
 Cirulli, V., 1458
 Clark, P.M., 911
 Clark, P.M.S., 437
 Clark, W.S., 790
 Clausen, J.O., 347
 Cleary, P.A., 1218
 Coates, P.A., 631
 Cobelli, C., 845
 Coggan, A.R., 1066
 Cohen, I.R., 1132
 Cohen, N., 423
 Cohen, P.T.W., 90
 Colca, J.R., 43
 Cole, J.A., 446
 Colman, P.G., 636
 Compagnucci, P., 513
 Concannon, P., 592, 999
 Conti, M., 67
 Cook, D.L., 118
 Cooke, A., 906
 Cooney, G.J., 718
 Copeman, J.B., 1186
 Coppelli, A., 375
 Corkey, B.E., 1285
 Cornell, J.C., 1375
 Cosimi, S., 375
 Cox, L.J., 437
 Cox, N.J., 592, 999, 1408
 Coyle, P.J., 1087
 Cozzone, P., 196
 Craig, B.W., 1345
 Craven, P.A., 335
 Crook, E.D., 314
 Cruickshanks, K.J., 916
 Cryer, P.E., 1351
 Cuartero, B.G., 753
 Cullinan, C.A., 67
 Cummings, M.H., 1059
 Cunningham, B.A., 1285
 Curling, V., 911
 Curphey, T.J., 824
 Cusin, I., 1467
 Czernichow, P., 1029

D

Dahlquist, G., 125, 408
 D'Allesio, D.A., 1433
 Dallman, M.F., 1420
 Dalton, K.J., 911
 Daniels, M., 314
 Danilov, S., 489
 Davalli, A.M., 75, 104
 Davies, J.E., 382, 1180

Daw, K., 216
 de Courten, M., 418
 De Grandi, F., 845
 de Hertogh, R., 531
 de Jong, P.T.V.M., 11
 De Mattia, G., 431
 de Souza, C.J., 984
 de Vries, R.R.P., 278
 Deacon, C.F., 1126
 Dean, J., 460
 Deeb, S.S., 330
 DeFronzo, R.A., 165, 665
 Del Prato, S., 165
 Dela, F., 221, 1010
 DeLarato, N.H., 1186
 Delovitch, T.L., 615
 Demenais, F., 1243
 DePaoli, A.M., 1447
 DeRubertis, F.R., 335
 Derylo, B., 759
 Desideri, G., 431
 DeSimone, C., 20
 Deweese, C., 125
 Di Carlo, V., 837
 Di Francesco, L., 431
 Diabetes Control And Complications Trial Research Group, 968
 Diamond, J., 1147
 Dielemans, I., 11
 DiGirolamo, M., 954
 Dills, D.G., 161
 Dissing, S., 767
 Docherty, K., 1002
 Dohm, G.L., 555, 682, 695
 Dolan, P.L., 555
 Dondlinger, L.A., 884
 Donker, A.J.M., 561
 Doria, A., 243
 Doyle, P., 1467
 Dozio, N., 1227
 Driesch, E., 890
 Dubois, F., 1029
 Dudczak, R., 543
 Duinkerken, G., 278
 Dunaway, G.A., 1285
 Dupre, J., 626
 During, M.J., 180
 Durrington, P.N., 460
 Dziura, J., 900

E

Ebeling, P., 471
 Ebihara, I., 895
 Ebina, Y., 1081
 Echwald, S.M., 90, 347
 Edlmayer, A., 543
 Edlund, H., 1002
 Edlund, T., 1002
 Edwards, C.T., 550
 Edwards, C.W., III, 43
 Edwards, O.M., 911
 Efendić, S., 1280
 Eisenbarth, G.S., 608, 1176, 1340
 Elbein, S.C., 1259
 El-Hashimy, M., 295
 Elias, D., 1132

Elliott, R., 495
Endoh, M., 1233
Ensinn, J.W., 1433
Erikson, R.L., 90
Eriksson, S., 1170
Erlach, H.A., 608
Espinosa, R., III, 592

F

Fajans, S.S., 699, 1408
Falletti, E., 924
Fanelli, C., 513
Fasching, P., 543
Fathman, C.G., 550
Faustman, D.L., 1114
Fazio, F., 537
Fehmann, H.-C., 16
Fernandes, R., 418
Ferryhough, P., 25
Ferrara, N., 98
Ferrer, J., 689, 1369
Ferri, C., 431
Feuvray, D., 196
Fey, S.J., 400, 753
Finardi, G., 60
Finegood, D.T., 506
Fischer, H.R.A., 561
Flament, J., 527
Flavell, R.A., 326
Flier, J.S., 1266
Forsgren, M., 408
Foulis, A., 658
Fränkel, K.M.A., 565
Frazier, M.L., 1046
Froesch, E.R., 1209
Froguel, P., 689, 1202, 1243
Frøkjær-Jensen, J., 767
Fujii, J., 733
Fujimoto, W.Y., 173
Fujiwara, T., 646
Fukui, M., 895
Furuta, H., 389
Furuta, M., 389

G

Gabbay, K.H., 132
Gabor Miklos, G.L., 90
Galante, P., 646
Galbo, H., 221, 1010
Gall, M.-A., 783, 1303
Gaskill, S.P., 1386
Gastaldelli, A., 1066
Gavigan, K.E., 555
Gebhart, S.S.P., 790
Gens, E., 1414
Georgiou, H.M., 49
Gerard, D.P., 185
German, M., 592, 1002
Gessl, A., 1323
Getty, L., 1038
Gettys, T.W., 85
Giacomello, R., 924
Gianani, R., 608, 1176, 1340
Giannarelli, R., 375
Gill, B.M., 615
Gingerich, R., 1156
Giordano, M., 665
Gladstone, P., 859
Goddard, A., 658
Göke, B., 16
Göke, R., 16
Goldstein, R.E., 672
Gomis, R., 1369
Goodison, S., 1002
Gordon, D., 141
Gorus, F., 527

Goto, S., 992
Gotoda, T., 580
Gough, D.A., 1005
Granner, D.K., 290, 340, 347, 1426
Gray, G.S., 816
Green, F., 37
Gregory, R., 911
Greiner, D.L., 963, 1392
Gremlich, S., 1202
Gries, F.A., 890
Grill, V.E., 394
Grillari, J., 1323
Grobbee, D.E., 11
Gromada, J., 767
Groop, L.C., 1099
Gu, D., 1161
Guerder, S., 326
Guo, J., 1114

H

Haaparanta, M., 31
Haber, R.S., 441
Hackleman, S., 284
Haffner, S.M., 284, 1156, 1386
Hager, H., 1243
Hagström-Toft, E., 1170
Halban, P.A., 1075
Halberstam, M., 423
Hales, C.N., 437
Halter, J.B., 699
Hamann, A., 1266
Hamulyak, K., 80
Hani, E.H., 1202, 1243
Hanis, C.L., 592, 999
Hansen, B.V., 489, 1405
Hansen, T., 90, 347
Hanson, M.S., 1392
Hanson, R.L., 261, 418, 483
Hara, T., 718
Harada, K., 580
Harada, N., 520
Häring, H.U., 646
Harlan, D.M., 816
Harrison, C.R., 1046
Hasegawa, Y., 744
Hashimoto, N., 1081
Hattersley, A.T., 1
Hauhart, R.E., 190
Hayashi, H., 1081
Hayek, A., 1458
Hayes, N.S., 67
Hehmke, B., 1414
Hei, Y.-J., 1147
Heimberg, H., 527
Held, W., 112
Hennessy, T.R., 1059
Henry, O.A., 586
Henry, R.R., 936
Herold, K.C., 354, 871
Hespel, P., 210
Hesseltom, R.A.M., 1392
Hickey, M.S., 555
Hiltunen, M., 652
Hirata, Y., 1227
Hirshman, M.F., 1362
Hixson, J.E., 284
Hoffman, M.D., 1259
Hofman, A., 11
Hofmann, C., 43
Hokanson, J.E., 1218
Holder, J.C., 1087
Hollister, J., 104
Holman, G.D., 1087
Holst, J.J., 1126
Hopmeier, P., 1033
Horikoshi, H., 646

Horton, E.S., 1362
Horton, R., 321
Hosoda, K., 855
Hosokawa, H., 1328
Hosokawa, Y.A., 1328
Hougaard, P., 1303
Houmar, J.A., 555
Houwing, H., 565
Hovi, T., 652
Hramiak, I.M., 626
Hu, M., 423
Huang, R., 1114
Huang, X., 658
Humphries, S.E., 37
Hurst, R.D., 759
Hussain, M.A., 1209
Hutchings, P.R., 906
Hutton, J.C., 278
Hwa, L., 1420
Hyöty, H., 652

I

Ide, C., 744
Ido, Y., 234
Iida, M., 1081
Ikäheimo, I., 621
Ikebuchi, M., 520
Ilonen, J., 1021
Imanaka, T., 1081
Imboden, M.A., 112
Imes, S., 506
Imura, H., 1002
Inchiostro, S., 203
Inoko, H., 1334
Inoue, Y., 414
Irminger, J.-C., 1075
Ishibashi, M., 992
Isse, N., 855
Ito, K., 1081
Ivarsson, S., 408, 1349
Iwasaki, N., 1408

J

Jackson, N.C., 1059
Jackson, R.A., 608, 1176
Jacob, R.J., 900
Jacobsen, P., 739
Jacobsson, L.T.H., 261
Jaffa, A.A., 156
Jakobsson, I.L., 1349
James, R.F.L., 658
Jan, L.Y., 592
Janeway, C.A., Jr., 326
Janssen, R.C., 478
Jansson, L., 1280
Jaramillo, A., 615
Jean, S., 824
Jeanrenaud, B., 1467
Jensen, M.D., 1165
Jéquier, E., 641
Ji, L., 243
Jia, X., 495
Jinde, K., 1233
Jingami, H., 855
Jinnouchi, H., 1081
Jordan, M., 884, 1106
Jost-Vu, E., 321
Juji, T., 1227
June, C.H., 816

K

Kagawa, S., 1081
Kahn, C.R., 243
Kahn, S.E., 173
Kakei, M., 878
Kallan, A.A., 278

Kamada, T., 733
Kammerer, C.M., 284, 1046
Kamohara, S., 1081
Kan, M., 1081
Kanai, F., 1081
Kaneto, H., 733
Kang, Y.-S., 1399
Kappler, F., 810
Karjalainen, J., 652
Karlsen, A.E., 400, 753
Kashiwagi, A., 520
Kasuga, M., 744
Katz, L.D., 185
Kaufmann, J., 1075
Kawada, T., 855
Kawamura, M., 580
Kellerer, M., 646
Kelly, J.M., 1059
Kennedy, G., 1002
Kennedy, H., 1218
Khandoudi, N., 196
Khoursheed, M., 947
Kikkawa, R., 520
Kim, D.T., 550
Kinard, T.A., 1461
King, G.L., 98
Kirkham, D.M., 1087
Kjos, S.L., 586
Klein, B.E.K., 161, 796, 916
Klein, H.H., 1310
Klein, R., 161, 796, 916
Klein, R.L., 1093
Knip, M., 621, 652, 1021
Knowler, W.C., 261, 418, 483
Knuuti, M.J., 31
Ko, B.C.-B., 727
Kobayashi, T., 1334
Koch, S., 290
Kockum, I., 125
Kohner, E.M., 603
Kohnert, K.-D., 1414
Koide, H., 895
Koivisto, V.A., 471
Koji, T., 1233
Koligs, F., 16
Kondo, T., 992
Kopp, H.-P., 1033
Koranyi, L., 471
Koriyama, N., 878
Korn, A., 543
Kosaka, K., 1334
Koskela, P., 652
Kotzke, G., 1310
Kozka, I.J., 1087
Krahl, T., 1161
Krakauer, J.C., 775
Kral, J.G., 141
Kreiner, G., 543
Krolewski, A.S., 243, 295, 382, 1180
Krolewski, B., 382, 1180
Krugluger, W., 1033
Kulmala, P., 1021
Kumagai, A.K., 1399
Kumar, S., 460
Kuromi, H., 1213
Kurtzals, P., 1381
Kusunoki, M., 718
Kuwata, S., 1227
Kwok, Y.N., 495

L

Laakkonen, M., 652
Laakso, M., 330
Lachance, D., 1274
Lacy, D.B., 672

- Lai, F.-P., 592
 Laimins, M., 1093
 Laine, H., 31
 Lal, S., 810
 Lam, K.S.-L., 727
 Lamberts, S.W.J., 11
 Landin-Olsson, M., 125
 Landoni, C., 537
 Lane, A., 37
 Larsen, J.J., 221, 1010
 Larsen, P.M., 400, 753
 Laube, F., 1414
 Laupland, K.B., 615
 Le Beau, M.M., 592
 Leahy, J.L., 1328
 Lebovitz, H.E., 141, 466
 Lecerf, L., 489
 Lee, A.T., 20
 Leehey, D.J., 929
 Leggett-Frazier, N., 555
 Leibowitz, M.D., 67
 Leinikki, P., 652
 Leiter, E.H., 1186, 1392
 Leitha, T., 543
 Lemkes, H.H.P.J., 501
 Leonetti, D.L., 173
 Lepore, M., 513
 Leppert, M.F., 1259
 Lerrumark, Å., 125, 658
 Lesage, S., 1243
 Leurs, P.B., 80
 Leuven, J.A.G., 501
 Levisetti, M., 947
 Levy, J.C., 1
 Lévy-Marchal, C., 1029
 Li, X., 1114
 Lin, H.-C., 227
 Lindberg, B., 408
 Lindenmayer, G.E., 1438
 Lindsay, R.M., 365
 Lister, C.A., 1087
 Liu, D., 506
 Lopes-Virella, M.F., 1093
 Lopez, A.D., 1458
 Love, J.M., 1186
 Lovejoy, J., 954
 Lowell, B.B., 1266
 Lucignani, G., 537
 Ludvik, B., 1121
 Lundquist, I., 830
 Luzi, L., 837
 Luzio, S.D., 631
 Lybrand, T.P., 125
- M**
 Ma, L., 615
 MacCluer, J.W., 284
 Macklin, B., 152
 Mackness, M.I., 460
 Madsen, O., 1002
 Madsen, O.D., 753
 Maeda, S., 744
 Maggi, E., 60
 Magnusson, I., 185
 Maillet, O., 531
 Mäki, M., 31
 Makino, H., 1081
 Makita, Z., 824
 Malkki, M., 330
 Mandel, T.E., 49
 Mandrup-Poulsen, T., 400, 753
 Manganiello, V.C., 67
 Manire, M., 1046
 Månsson, M.U.L., 1349
 Marchand-Brustel, Y.L., 1266
 Marchetti, P., 375
 Marcovina, S.M., 1218
 Martin, B.C., 295
 Martin, F., 300
 Masiello, P., 375
 Massucco, P., 1318
 Masuzaki, H., 855
 Matsuda, M., 665
 Matsumoto, K., 992
 Matsuo, H., 992
 Matsuo, T., 733
 Mattiello, L., 1318
 Mayfield, R.K., 156
 Mayorga, R.A., 1259
 McAleer, M.A., 1186
 McCance, D.R., 261
 McCarthy, S., 1054
 McClain, D.A., 314
 McDermott, A.M., 453
 McDonald, J., 1180
 McDonald, T.J., 626
 McDougal, D.B., Jr., 190
 McFarlane, P., 626
 McGinnis, R.E., 1296
 McIntosh, C.H.S., 495
 McIntyre, M.A., 365
 McKenna, M.J., 775
 McManus, R., 506
 McNeill, J.H., 1147
 Medina, R.A., 1375
 Meer, J., 759
 Meglasson, M.D., 984
 Melloul, D., 1002
 Members of the Swedish
 Childhood Diabetes Study,
 125
 Meneilly, G.S., 272
 Menzel, R., 1408
 Menzel, S., 592, 1408
 Messmer, E.P., 1209
 Michaelis, D., 1414
 Miettinen, H., 1156, 1386
 Mijares, A.H., 1165
 Miki, A., 744
 Miki, M., 744
 Mikines, K.J., 221, 1010
 Milberg, W.P., 272
 Miles, P.D.G., 947
 Mitchell, B.D., 284, 1046
 Mixon, P.S., 790
 Miyazaki, J., 744
 Miyazaki, M., 1233
 Mizoguchi, A., 744
 Mizuno, N., 1213
 Mohamed-Ali, V., 37
 Mohiuddin, L., 25
 Moller, D.E., 340
 Molony, L., 1161
 Monti, L.D., 537
 Montoro, M., 586
 Moore, L.L., 824
 Moossa, A.R., 947
 Mordes, J.P., 963
 Moresco, R.M., 537
 Morgen, J., 900
 Mori, K., 855
 Moriyama, H., 744
 Moromisato, R., 608
 Morris, P.G., 682, 695
 Mortensen, S.B., 753
 Morton, C.C., 243
 Moss, L., 1002
 Moss, S.E., 161, 796, 916
 Mosthaf, L., 646
 Motz, E., 924
 Moyer, M.P., 1046
 Mueller, C., 112
 Mularoni, E.M., 1318
 Munk, S., 759
 Murakami, T., 1081
 Murase, T., 414, 1334
 Myers, M.A., 1290
- N**
 Nadler, J., 321
 Nagata, M., 744
 Nagataki, S., 992
 Nagi, D., 437
 Naka, R., 1233
 Nakamura, M., 733
 Nakamura, T., 895
 Nakanishi, K., 1334
 Nakao, K., 855
 Nakazaki, M., 878
 Nanjo, K., 389
 Napoli, R., 1362
 Narayan, K.M.V., 261, 418, 483
 Natarajan, R., 321
 Nauck, M.A., 1126
 Navales, R., 375
 Negrete, H., 335
 Neidigh, J.L., 314
 Nelson, R.G., 483
 Nepom, G., 859, 1227
 Nerup, J., 400, 753, 1408
 Ng, L.L., 382, 1180
 Nicod, P., 641
 Nicoll, C.S., 1420
 Nielsen, F.S., 489, 783, 1303, 1405
 Nieuwenhuis, H.-K., 890
 Nikoulina, S., 936
 Nikula-Ijas, P., 1099
 Nishio, Y., 520
 Nishioka, Y., 1081
 Noi, M., 1029
 Nolan, J.J., 1121
 Nolte, L.A., 1345
 Noma, Y., 75
 Nomoto, Y., 1233
 Nomooz-Zadeh, J., 1054
 Nuutila, P., 31
 Nyengaard, J.R., 234
- O**
 O'Connell, P., 1046
 Ogawa, Y., 75, 104, 855
 Ohagi, S., 389
 Ohnishi, T., 1081
 Ohsuga, J., 580
 Okamoto, N., 744
 Okazaki, T., 855
 Okumura, K., 744
 Okuno, A., 646
 Olefsky, J., 947, 1121
 Olson, K., 1002
 Otori, Y., 1227, 1408
 O'Rahilly, S., 911
 Orho, M., 1099
 Ortiz, F.J., 699
 Osawa, H., 1426
 Ossowski, V.M., 478
 Östenson, C.-G., 1280
 Ostrega, D., 437
 Owens, D.R., 631
 Owerbach, D., 132
 Owlya, R., 641
- P**
 Palazuk, B., 43
 Palmer, S.M., 1186
 Pampanelli, S., 513
 Pampfer, S., 531
 Panagiotidis, G., 830
 Panahloo, A., 37
 Paquin, T., 441
 Pardridge, W.M., 1399
 Parfitt, A.M., 775
 Parving, H.-H., 489, 739, 783,
 1303, 1405
 Passa, P., 1243
 Patel, V., 603
 Patterson, N.B., 816
 Pearce, R.B., 572
 Pechhold, K., 816
 Pedersen, O., 90, 347, 1310
 Pederson, R.A., 495
 Pelech, S.L., 1147
 Permutt, M.A., 689, 1002, 1099,
 1408
 Perseghin, G., 837
 Peters, R.K., 586
 Petersen, J.S., 753
 Petersen, L.N., 1010
 Peterson, C.M., 572
 Peterson, L.B., 1186
 Petley, A., 152
 Pettermann, M., 1323
 Pettitt, D.J., 261, 418, 483
 Pfeiffer, M.A., 1355
 Philippe, J., 1002
 Philippi, A., 1243
 Phillips, L.S., 790
 Piatti, P., 537
 Pieper, G.M., 884, 1106
 Pietropaolo, M., 1176, 1340
 Piretto, V., 1318
 Pirisi, M., 924
 Ploug, T., 1010
 Plump, A., 20
 Poirier, O., 489
 Poitout, V., 306
 Polak, B.C.P., 561
 Poli, M., 60
 Polonsky, K., 437
 Polonsky, K.S., 506, 699, 705,
 1447
 Pols, H.A.P., 11
 Ponziani, M.C., 1318
 Pories, W.J., 682, 695
 Poronnik, P., 118
 Porret, A., 1202
 Posner, B.I., 1274
 Powell, E.E., 1186
 Powers, A.C., 216
 Pozza, G., 537, 837
 Pridal, L., 1126
 Prigeon, R.L., 173, 1433
 Prins, J.-B., 1186
 Printz, R.L., 290, 340, 347, 1426
 Pritsker, A., 441
 Prochazka, M., 478, 1186
 Pugh, J.A., 1375
 Pugliese, A., 608
 Pujol-Borrell, R., 658
 Purnell, J.Q., 1218
- Q**
 Quinn, P.A., 382, 1180
- R**
 Rabin, D.U., 689, 1290, 1340
 Rabinovitch, A., 658
 Raguso, C.A., 1066
 Rao, D.S., 775
 Rassam, S.M.B., 603
 Rebrin, K., 1038
 Reich, E.-P., 326
 Reichart, D., 947
 Reifsnnyder, P., 1186

- Reijonen, H., 621, 1021
 Renström, E., 767
 Renwick, A.G., 152
 Reynet, C., 243
 Ribel, U., 1381
 Rich, S.S., 139, 243
 Richmond, K., 90
 Richter, E.A., 210
 Ricordi, C., 1458
 Riggs, A.C., 689
 Rincón, J., 1345
 Riou, J.P., 1196
 Robertson, R.P., 306, 1002
 Robinson, D.D., 984
 Robinson, K.A., 1438
 Rodgers, B.D., 1420
 Rodrigues, N.R., 1186
 Roep, B.O., 278
 Rohane, P.W., 550
 Rohner-Jeanrenaud, F., 1467
 Roivainen, M., 652
 Rønningen, K.S., 621, 1227
 Rorsman, P., 767
 Rosner, J., 1239
 Rossetti, L., 423
 Rossing, K., 739
 Rossing, P., 489, 739, 783, 1405
 Rossini, A.A., 963
 Rossiter, S.P., 365
 Rothenberg, P.L., 802
 Rothman, D.L., 185
 Rowley, M.J., 1290
 Roza, A.M., 884, 1106
 Rubin, J.S., 1458
 Ruotsalainen, U., 31
 Rust, P.F., 156
 Rutter, W.J., 1002
 Ryan, E.A., 506
- S**
 Sabater, J., 267
 Sacks, D., 1121
 Saeki, Y., 520
 Sainsbury, A., 1467
 Sakai, H., 1233
 Sakura, H., 597
 Salehi, A., 830
 Sanchez-Andres, J.V., 300
 Sanders, L., 665
 Sanjeevi, C.B., 125
 Sanke, T., 389
 Sano, H., 1081
 Santucci, A., 431
 Saperstein, R., 67
 Sarvetnick, N., 1161
 Satin, L.S., 1461
 Satoh, N., 855
 Scaglia, L., 104
 Schalin-Jäntti, C., 1099
 Schernthaner, G., 1033
 Scherrer, U., 641
 Scherstén, B., 483
 Schmidli, R.S., 636
 Schork, N.J., 1186
 Schuit, F., 527
 Schultz, V., 1285
 Schulz, D.W., 190
 Schumer, M.P., 1355
 Schwartz, M.W., 147
 Schwippert, B., 890
 Seaquist, E.R., 85
 Seino, S., 1213
 Seo, H.G., 733
 Serreze, D.V., 1186, 1392
 Serup, P., 1002
 Shamoon, H., 423
- Shank, M.L., 165
 Sharma, K., 1139
 Sharp, G.W.G., 453
 Shaver, A., 1274
 Shaw, J.T.E., 1
 Sherwin, R.S., 180, 900
 Shigemoto, M., 855
 Shigeta, Y., 520
 Shima, A., 414
 Shimada, A., 550
 Shimada, M., 580
 Shimano, H., 580
 Shipman, P., 1046
 Shlimovich, P., 423
 Shulman, G.I., 180, 185
 Shultz, L.D., 550, 1392
 Siczkowski, M., 382, 1180
 Sidossis, L.S., 1066
 Silverberg, M., 759
 Simon, J., 802
 Singh, A.K., 929
 Sipols, A.J., 147
 Smidt, U.M., 783
 Smith, M.J., 699
 Smith, S.A., 1087
 Smith, T., 1176
 Smith, W., 365
 Soeldner, J.S., 1176
 Solin, O., 31
 Somoza, N., 658
 Song, R.H., 929
 Sönksen, P.H., 1059
 Sorenson, R.L., 306
 Soria, B., 300
 Spielman, R.S., 592, 999, 1296
 Spinass, G.A., 1227
 Stefani, L., 537
 Steffens, A.B., 565
 Steffes, M.W., 1218
 Stehouwer, C.D.A., 561
 Steil, G.M., 954, 1038
 Stein, R., 1002
 Steiner, D., 1002
 Stel, G., 924
 Stenger, D., 125
 Stern, M.P., 284, 369, 1046, 1156, 1386
 Stevanovic, Z.S., 759
 Stewart, T.A., 658
 Stirling, B., 999
 Stoffel, M., 592, 597, 699, 1447
 Stolk, R.P., 11
 Stoltz, A., 699
 Storlien, L.H., 718
 Stout, L.E., 306
 Strack, A.M., 1420
 Stratton, I.M., 340
 Strubbe, J.H., 565
 Studer, K., 1209
 Studer, R.K., 335
 Sturis, J., 506, 699, 1447
 Su, B., 810
 Sun, Q., 354
 Sun, X., 1447
 Sundkvist, G., 125
 Susulic, V.S., 1266
 Suzuki, D., 1233
 Suzuki, K., 733
 Svaasand, E.K., 572
 Svendsen, T.L., 783
 Sweeney, F.P., 382, 1180
 Swenson, K.E., 326
 Swinn, R.A., 911
 Szwergold, B.S., 810
- T**
 Taboga, C., 924
 Tadakoro, K., 1227
 Tajaddini-Sarmadi, J., 1054
 Takagi, H., 98
 Takagi, Y., 520
 Takeda, J., 1447
 Tamsma, J.T., 501
 Tamura, N., 855
 Tanaka, H., 878
 Tanaka, Y., 520
 Tang, J., 1447
 Taniguchi, N., 733
 Tanizawa, Y., 689
 Tappy, L., 641
 Tarnow, L., 489, 1405
 Tatsumi, H., 733
 Taylor, A.H., 810
 Teräs, M., 31
 Terruzzi, L., 837
 Tessari, P., 203
 Thieme, H., 98
 Thompson, B.D., 478
 Thorens, B., 75, 1202
 Thorsby, E., 621
 Thurston, J.H., 190
 Tichet, J., 1029
 Tiengo, A., 203
 Tilton, R.G., 234
 Tippmer, S., 646
 Todaka, M., 1081
 Todd, J.A., 621, 1186
 Toffolo, G., 845
 Toft-Nielsen, M., 1126
 Tokunaga, K., 1227
 Tokuyama, Y., 1447
 Tominaga, Y., 744
 Tomino, Y., 895
 Tomlinson, D.R., 25
 Tonutti, L., 924
 Tooke, J.E., 721
 Tornheim, K., 1285
 Trabb, J.B., 1408
 Trigler, L., 572
 Trocino, R.A., 992
 Trovati, M., 1318
 Tsai, M.-J., 1002
 Tsaor, M.-L., 592
 Tschoepe, D., 890
 Tsuji, K., 1334
 Tsukamoto, K., 744
 Tsutsumi, K., 414
 Tuch, B.E., 118
 Tuokko, H., 272
 Tuomilehto, J., 483
 Tuomilehto-Wolf, E., 1021
 Tuominen, J.A., 471
 Turner, R.C., 1, 597
 Tyndall, G.L., 555
- U**
 Uchigata, Y., 1227
 U.K. Prospective Diabetes Study Group, 1249
 Ulrich, R.G., 984
 Umpierrez, G.E., 790
 Umpleby, A.M., 1059
 Undlien, D.E., 621
 Unger, R.H., 863
 Urata, Y., 992
- V**
 Vähäsalo, P., 652, 1021
 Valera, A., 267
 Van den Enden, M., 234
 Van der Auwera, B., 527
- van Kuijk, A.W.R., 561
 van Oerle, R., 80
 van Schilfgaarde, R., 227
 van Suylichem, P.T.R., 565
 Van Waeyenberge, C., 527
 Vandenberghe, K., 210
 Vanderheyden, I., 531
 Vandewalle, C., 527
 Vaxillaire, M., 689, 1243
 Veijola, R., 1021
 Vergauwen, L., 210
 Verge, C.F., 1176, 1340
 Vestergaard, H., 90, 347, 1310
 Vezys, V., 354
 Viacava, P., 375
 Vidal, H., 1196
 Vidal-Puig, A., 340
 Vigeant, C., 1274
 Vik, T.A., 90
 Vingerling, J.R., 11
 Vionnet, N., 1202, 1243
 Visintin, L., 326
 Vissing, H., 753
 Vlassara, H., 824
 Vollenweider, F., 1075
 Vollenweider, L., 641
 Vos-Scheperkeuter, G.H., 227
- W**
 Wagner, L., 1323
 Wahlström, E.O., 1345
 Waldhäusl, W., 543, 1323
 Walker, M.D., 1002
 Walker, R.E.W., 446
 Wallberg-Henriksson, H., 1345
 Walseth, T.F., 85, 306
 Wang, J.P., 90
 Wang, L., 67
 Wang, Q., 161
 Wareham, N.J., 911
 Warram, J.H., 243, 295
 Warren-Perry, M., 597
 Wasserman, D.H., 672
 Wasson, J., 689
 Wat, N.M.-S., 727
 Watanabe, R.M., 954
 Watts, G.F., 1059
 Webb, G.C., 90
 Weber, A.B., 900
 Weidner, M.D., 555
 Weinhaus, A.J., 118
 Weinstein, M.L., 1438
 Weinstein, S.P., 441
 Weir, G.C., 75, 104
 Weremowicz, S., 243
 Whalen, B.J., 963
 Whitehouse, F.W., 775
 Whitesell, R.R., 1426
 Whiteside, C.I., 759
 Wicker, L.S., 1186
 Wilkin, T.J., 152
 Williams, B.C., 365
 Williamson, J.R., 234
 Williamson, M.P., 626
 Willison, L.D., 802
 Willms, B., 1126
 Wolf, B.A., 802
 Wolfe, R.R., 1066
 Wolff, S.P., 1054
 Wolfenbutter, B.H.R., 80
 Wolters, G.H.J., 227
 Wolzt, M., 543
 Wong, S., 326
 Wu, G., 360
 Wu, Y.-J., 75, 104
 Wulff, B.S., 767

Wuu, Y.-D., 531

X

Xiang, A., 586

Y

Yagame, M., 1233

Yagi, N., 744

Yagita, H., 744

Yale, J.-F., 1274

Yamada, N., 580

Yamagata, K., 1408

Yamamoto, H., 992

Yamamoto, K., 580

Yamasaki, Y., 733

Yaney, G.C., 1285

Yang, P.-Y., 90

Yazaki, Y., 580

Yki-Järvinen, H., 31

Yokono, K., 744

Yoneda, R., 744

Yordy, M.R., 446

Yoshida, H., 389

Yoshida, S., 1081

Yoshimasa, Y., 855

Young, P.W., 1087

Yu, J.H., 984

Yu, L., 1176, 1340

Yuan, J., 658

Yudkin, J., 37, 437

Z

Zabel, P., 626

Zafar, P.T., 67

Zhang, Y., 597

Zheng, D., 555

Zhou, J., 314

Zhou, X., 759

Zhou, Y.-P., 394

Zierath, J.R., 347, 1345

Ziyadeh, F.N., 1139